Category: Top Story
-
Microsoft Seen as Top Beneficiary of GenAI Spending, Says Morgan Stanley
Morgan Stanley reiterated its bullish stance on Microsoft (NASDAQ:MSFT), telling investors in a research note that the tech giant “remains the clearest beneficiary of GenAI spend” as companies continue directing larger portions of their technology budgets toward artificial intelligence, cloud computing, and digital transformation. Citing its 3Q25 CIO survey, Morgan Stanley stated that “Microsoft remains…
-
Sealsq Shares Climb After Announcing Strategic U.S. Defense Partnership
Shares of Sealsq Corp (NASDAQ:LAES) gained 3.6% on Thursday after the semiconductor and post-quantum cryptography company revealed a strategic collaboration with Trusted Semiconductor Solutions (TSS) to develop “Made in U.S.” quantum-resistant security solutions aimed at defense and government markets. The partnership will merge Sealsq’s cryptography expertise with TSS’s Category 1A Trusted-accredited capabilities to produce high-assurance…
-
InMode Shares Gain After Preliminary Q3 Revenue Beats Expectations
Shares of InMode Ltd. (NASDAQ:INMD) climbed 9% on Thursday after the medical technology company released preliminary third-quarter revenue figures that came in well above Wall Street forecasts, while also reaffirming its full-year outlook. InMode reported preliminary Q3 revenue between $92.5 million and $93.0 million, topping the consensus estimate of $87.9 million, representing a beat of…
-
Momentus Shares Jump After Winning $5.1 Million NASA Contract
Shares of Momentus Inc. (NASDAQ:MNTS) climbed 10.6% in premarket trading on Thursday after the commercial space transportation company announced it had secured a $5.1 million contract from NASA under its Flight Opportunities program. The contract, awarded on September 26, will support the Commercial Orbital System for Microgravity In-Space Crystallization (COSMIC) demonstration. Momentus will use its…
-
Bluejay Diagnostics Shares Skyrocket After Strengthening Manufacturing Deal with SanyoSeiko
Shares of Bluejay Diagnostics Inc (NASDAQ:BJDX) surged 110% in premarket trading on Thursday after the medical diagnostics firm announced it had expanded its manufacturing partnership with SanyoSeiko Co., Ltd. of Japan. The company, which develops rapid testing solutions for near-patient diagnostics, said it had amended its Master Service and Master Supply Agreements with SanyoSeiko to…
-
Alterity Therapeutics Shares Edge Higher After Encouraging MSA Trial Results
Shares of Alterity Therapeutics Ltd (NASDAQ:ATHE) climbed 3.3% in premarket trading on Thursday after the company unveiled promising clinical data from its Phase 2 trial for Multiple System Atrophy (MSA) during a key medical conference. The biotech firm shared the results of its ATH434-201 randomized, double-blind study at the International Congress of Parkinson’s Disease and…
-
Klarna Shares Climb on New AI Partnership with Google Cloud
Shares of Klarna (NYSE:KLAR) rose 3% on Thursday after the fintech company announced a strategic collaboration with Google Cloud aimed at accelerating the integration of artificial intelligence across its global payments and shopping platform, which serves more than 114 million users. Under the agreement, Klarna will harness Google Cloud’s advanced AI infrastructure to develop innovative…
-
Medirom Shares Surge After Subsidiary Greenlights Private Placement
Shares of Medirom Healthcare Technologies Inc. (NASDAQ:MRM) jumped 22% in premarket trading on Thursday after its health tech subsidiary, MOTHER Labs, approved a private placement of new shares to two senior executives. The private placement is part of MOTHER Labs’ Series A funding round and assigns the subsidiary a valuation of approximately 9 billion yen…
-
Central Bank Gold Buying Doubles Long-Term Average, Pushing Prices to Historic Highs
Gold prices climbed past $4,000 per ounce this week, reaching inflation-adjusted levels not seen since 1980, as a surge in central bank demand drives the latest rally in the precious metal. According to strategists at Deutsche Bank, official sector purchases are currently running at twice the pace of the 2011–2021 average, with China at the…
-
Novo Nordisk expands its liver disease portfolio with the acquisition of Akero Therapeutics for up to $5.2 billion
Novo Nordisk (NYSE:NVO) announced the acquisition of U.S.-based Akero Therapeutics (NASDAQ:AKRO) for up to $5.2 billion, expanding its presence in the treatment of liver diseases associated with obesity. The deal marks the first major transaction under new CEO Maziar Mike Doustdar. The Danish pharmaceutical company will pay $54 per share, totaling approximately $4.7 billion, a…